MedTrace Logo

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

NCT02309632 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2019-07-29

No results posted yet for this study

Summary

100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years. This data will be used to determine the pancreatic cancer and precancerous lesion detection rate in High Risk Individuals (HRIs). Subjects may agree to annual imaging and annual biomarkers or to biomarkers only.

Conditions

  • Pancreatic Neoplasms
  • Peutz-Jegher's Syndrome
  • BRCA1 Gene Mutation
  • BRCA2 Gene Mutation
  • Ataxia Telangiectasia
  • Familial Atypical Mole-Malignant Melanoma Syndrome
  • Colorectal Neoplasms, Hereditary Nonpolyposis
  • Hereditary Pancreatitis

Interventions

OTHER

Pancreatic Cancer Screening Pathway 1

Screening with imaging and biomarker testing

OTHER

Pancreatic Cancer Screening Pathway 2

Screening with biomarker testing only

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Kent D McKelvey, MD · University of Arkansas

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2019-07-19
Completion
2019-07-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02309632 on ClinicalTrials.gov